IN SUMMARY: I have been critical of big pharma because they keep their loyalty to Wall Street instead of patients. When the really good people within the industry learn to take risks and be heard the industry might change.
IN SUMMARY: Brilinta is taking on Plavix in the market for blood thinners and AZ is getting aggressive in trying to get patients to switch. The website for Brilinta is well done but one can’t help but wonder if why it has to look like a page out of a medical journal rather than a consumer branded site.
IN SUMMARY: Peccisism; a tendency to see the worst aspect of things or believe that the worst will happen; a lack of hope or confidence in the future. When it comes to pharma that pretty much describes me. In my 20+ years in healthcare marketing, I have seen a transformation from an industry focused on patients to an industry focused on profits.
- Facebook’s leaders seriously discussed selling access to user data — and privacy was an afterthought.
- Mark Zuckerberg oversaw plans to consolidate the social network’s power and control competitors by treating its users’ data as a bargaining chip, while publicly proclaiming to be protecting that data.
- Facebook ultimately decided not to sell the data directly but rather to dole it out to app developers who were considered personal “friends” of Zuckerberg or who spent money on Facebook and shared their own valuable data.
IN SUMMARY: GSK needs to do more DTC around their Shingrix vaccine especially since the earlier one was a lot less effective. DTC creates awareness and we need more awareness around shingles.
- Big Pharma is evading culpability for the crisis of rising prescription drug prices by point the finger at others, namely pharmacy benefit managers (PBMs).
- Many drugs receive no rebates at all, including 89 percent of Medicare Part D prescriptions. For new drugs, where the price tag can run into the hundreds of thousands a year, rebates are rarely offered because there is no direct competition in the space.
- Putting profits before people is what big Pharma does. Brand name drug makers have hiked the prices of their products at 10 times the rate of inflation over the last five years.
- Drugmakers historically have blamed higher prices on the costs of research and development but didn’t use
andof the $7 billion tax benefit to increase R&D.
- Pharmacy benefit managers said rebates paid by drug companies to PBMs, sometimes called “middlemen,” are “not secret or hidden payments”
- Executives blamed high drug prices on the drugmakers and their pursuit of profits.
- U.S. Healthcare Spending Reaches $420M Per Hour, On Track to Hit $12 Trillion by 2040.
- 62 health care CEOs made a combined $1.1 billion in 2018 when calculating the actual value of cashed-out stock.
- In the meantime Republicans are warning drug companies not to cooperate with probes into drug pricing.
KEY THOUGHT: AARP is inflaming the war on prescription drug prices by comparing the prices of generic drugs against branded drugs. This comparison is misleading and does a disservice to its members.